PL431139A1 - Kompozycja farmaceutyczna bimatoprostu i tymololu - Google Patents

Kompozycja farmaceutyczna bimatoprostu i tymololu

Info

Publication number
PL431139A1
PL431139A1 PL431139A PL43113919A PL431139A1 PL 431139 A1 PL431139 A1 PL 431139A1 PL 431139 A PL431139 A PL 431139A PL 43113919 A PL43113919 A PL 43113919A PL 431139 A1 PL431139 A1 PL 431139A1
Authority
PL
Poland
Prior art keywords
bimatoprost
timolol
pharmaceutical composition
application
preservative
Prior art date
Application number
PL431139A
Other languages
English (en)
Inventor
Krzysztof FAŁEK
Original Assignee
Warszawskie Zakłady Farmaceutyczne Polfa Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawskie Zakłady Farmaceutyczne Polfa Spółka Akcyjna filed Critical Warszawskie Zakłady Farmaceutyczne Polfa Spółka Akcyjna
Priority to PL431139A priority Critical patent/PL431139A1/pl
Priority to PCT/PL2020/050066 priority patent/WO2021049963A1/en
Priority to EP20797887.5A priority patent/EP4027977A1/en
Publication of PL431139A1 publication Critical patent/PL431139A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna bimatoprostu i tymololu, do stosowania w celu obniżenia ciśnienia wewnątrzgałkowego u pacjenta, która stanowi niezawierający konserwantów sterylny roztwór wodny o następującej recepturze: 0,03% wag. bimatoprostu, 0,5% wag. tymololu, 0,358% wag. dodekahydratu dwuzasadowego fosforanu sodu, 0,014% wag. monohydratu kwasu cytrynowego, 0,72% wag. chlorku sodu, woda z pH na poziomie 7,3. Zgłoszenie obejmuje także sposób otrzymywania powyższej kompozycji.
PL431139A 2019-09-13 2019-09-13 Kompozycja farmaceutyczna bimatoprostu i tymololu PL431139A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL431139A PL431139A1 (pl) 2019-09-13 2019-09-13 Kompozycja farmaceutyczna bimatoprostu i tymololu
PCT/PL2020/050066 WO2021049963A1 (en) 2019-09-13 2020-09-13 Pharmaceutical composition of bimatoprost and timolol
EP20797887.5A EP4027977A1 (en) 2019-09-13 2020-09-13 Pharmaceutical composition of bimatoprost and timolol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL431139A PL431139A1 (pl) 2019-09-13 2019-09-13 Kompozycja farmaceutyczna bimatoprostu i tymololu

Publications (1)

Publication Number Publication Date
PL431139A1 true PL431139A1 (pl) 2021-03-22

Family

ID=73030187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL431139A PL431139A1 (pl) 2019-09-13 2019-09-13 Kompozycja farmaceutyczna bimatoprostu i tymololu

Country Status (3)

Country Link
EP (1) EP4027977A1 (pl)
PL (1) PL431139A1 (pl)
WO (1) WO2021049963A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003078A1 (en) * 2022-06-27 2024-01-04 Warszawskie Zaklady Farmaceutyczne Polfa Sa Preservative-free ophthalmic composition comprising a prostaglandin analogue
CN115998888A (zh) * 2023-01-16 2023-04-25 广州楷石医药有限公司 用于治疗青光眼或高眼压症的药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807081C (en) * 2010-07-29 2018-09-18 Allergan, Inc. Preservative free bimatoprost and timolol solutions
GR1009006B (el) * 2016-04-01 2017-04-04 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
CN108236721A (zh) * 2016-12-26 2018-07-03 上海创诺医药集团有限公司 一种稳定的贝伐单抗制剂

Also Published As

Publication number Publication date
EP4027977A1 (en) 2022-07-20
WO2021049963A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
HRP20200998T1 (hr) Postupak i sastav za liječenje okularne hipertenzije i glaukoma
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
TWI399207B (zh) 改良之比馬前列素（ｂｉｍａｔｏｐｒｏｓｔ）眼用溶液
RU2013107744A (ru) Растворы биматопроста и тимолола, не содержащие консервантов
JP5568246B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤
NZ609719A (en) Pharmaceutical composition
PL431139A1 (pl) Kompozycja farmaceutyczna bimatoprostu i tymololu
KR890011823A (ko) 벤조일 페닐아세트산 유도체 약제 조성물
BRPI0610901A2 (pt) mÉtodo de uso de uma soluÇço aquosa de potencial oxi-redutivo em aplicaÇÕes dentais
BRPI0714808A2 (pt) mÉtodos e composiÇÕes para o tratamento e a prevenÇço de infecÇÕes
BR112014001802A2 (pt) fluido de manutenção de poço e método de manutenção de poço com fluido
GB1287673A (en) Injectable compositions
HUP0203773A2 (hu) Epinastintartalmú oldatok
JP2013535472A5 (pl)
ITRM20090102U1 (it) Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione.
JP2018188486A (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤
SE9903831D0 (sv) Formulation of substituted benzimidazoles
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
AR111166A1 (es) Uso intradialítico de nitrito de sodio
CA2535533A1 (en) Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
WO2012074237A3 (ko) 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
JP2022186861A5 (pl)
AR067047A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
NZ591213A (en) A formulation of canfosfamide consisting of 50 mg/mL canfosfamide hydrochloride in aqueous sodium citrate buffer
CO6270205A2 (es) Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo